Mukka Proteins Approves ₹47 Cr Preferential Warrants & ₹26.1 Cr Strategic Investments
Mukka Proteins approved issuing 2 crore warrants worth ₹47 crore to non-promoters at ₹23.50 each. The board also approved investments of ₹11.10 crore in Delta Marine Products and ₹15 crore in Aqua Marine. These strategic investments aim to expand the company's core business. Shareholder approval will be sought via postal ballot.
The preferential issue of warrants and strategic acquisitions are material events that can significantly impact the company's financial structure, operations, and growth prospects.
The company is raising funds through preferential allotment and making strategic investments to expand its business, which are positive developments.
Mukka Proteins Limited's Board of Directors, in a meeting held on June 12, 2026, approved the issuance and allotment of up to 2,00,00,000 (Two Crore) Fully Convertible Warrants on a preferential basis to Non-Promoter category individuals and entities. The issue price is fixed at ₹23.50 per warrant, aggregating up to ₹47 crore. Each warrant is convertible into one equity share of face value ₹1 each within 18 months from the allotment date, subject to shareholder and regulatory approvals.
The board also approved seeking shareholder approval via postal ballot for these warrants. The e-voting period for the postal ballot will be from June 13, 2026, to July 12, 2026, with a cut-off date of June 10, 2026.
Furthermore, Mukka Proteins will invest up to ₹11.10 crore in Delta Marine Products and up to ₹15 crore in Aqua Marine, both partnership firms. These investments are strategic capital contributions aimed at expanding the company's core business, enhancing capacity, optimizing operations, and improving production efficiency. The indicative time period for the completion of these investments is September 30, 2026. Delta Marine Products and Aqua Marine are both involved in the manufacturing of fish meal and fish oil.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.